Summary:
A phase 3 randomized, double-blind, multicenter, placebo controlled, combination study to evaluate the efficacy and safety of study medication and allopurinol compared to allopurinol alone in subjects with gout who have had an inadequate hypouricemic response to standard of care allopurinol.
Qualified Participants Must:
• Be 18-84 years of age
•
Meet diagnosis of Gout
•
Be taking 300mg of Allopurinol, for at least 8 weeks
•
Have had at least 2 gout flares in the past 12 months
Qualified Participants May Receive:
Study medication and allopurinol, study related medical care and labs at no cost and compensation for time and travel.